| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash, cash equivalents and restricted cash | 73,189 | 53,002 | ||
| Short-term investments | 278,619 | 262,131 | ||
| Accounts receivable, net | 30,728 | 40,091 | ||
| Inventory, net | 44,793 | 46,503 | ||
| Prepaid expenses and deposits | 11,107 | 6,578 | ||
| Other current assets | 301 | 665 | ||
| Total current assets | 438,737 | 408,970 | ||
| Finance right-of-use lease assets | 78,813 | 83,195 | ||
| Intangible assets, net | 3,901 | 4,046 | ||
| Operating right-of-use lease assets | 3,718 | 3,837 | ||
| Property and equipment, net | 2,266 | 2,421 | ||
| Other noncurrent assets | 93 | 93 | ||
| Total assets | 527,528 | 502,562 | ||
| Accounts payable | 2,214 | 3,312 | ||
| Accrued expenses | 49,536 | 49,704 | ||
| Finance lease liabilities, current portion | 16,309 | 16,167 | ||
| Deferred revenue | 4,602 | 5,499 | ||
| Operating lease liabilities, current portion | 1,057 | 1,047 | ||
| Other current liabilities | 2,502 | 2,537 | ||
| Total current liabilities | 76,220 | 78,266 | ||
| Finance lease liabilities, less current portion | 55,727 | 59,282 | ||
| Deferred revenue, less current portion | 12,249 | 12,349 | ||
| Deferred compensation and other noncurrent liabilities | 12,442 | 12,030 | ||
| Operating lease liabilities, less current portion | 5,119 | 5,334 | ||
| Total liabilities | 161,757 | 167,261 | ||
| Common shares - no par value, unlimited shares authorized, 131,841 and 140,883 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 1,116,797 | 1,122,582 | ||
| Additional paid-in capital | 109,885 | 105,337 | ||
| Accumulated other comprehensive loss | -749 | -905 | ||
| Accumulated deficit | -860,162 | -891,713 | ||
| Total shareholders' equity | 365,771 | 335,301 | ||
| Total liabilities and shareholders' equity | 527,528 | 502,562 | ||
Aurinia Pharmaceuticals Inc. (AUPH)
Aurinia Pharmaceuticals Inc. (AUPH)